Eclipse Surgical Technologies
This article was originally published in The Gray Sheet
Executive Summary
Data are submitted to FDA in support of market clearance for catheter-based percutaneous transluminal myocardial revascularization (PTMR) by interventional cardiologists. The company received FDA approval for open-chest transmyocardial revascularization using the Eclipse TMR 2000 solid-state laser system in February 1999 (1"The Gray Sheet" Feb. 15, 1999, p. 3). The PTMR submission includes 12-month data from a randomized, controlled multi-center study comparing PTMR to drug therapy in patients with severe angina and no other procedural options
You may also be interested in...
Eclipse Surgical TMR Laser Shipments Commence Following FDA Approval
Shipments of Eclipse Surgical Technologies' Eclipse 2000 transmyocardial revascularization laser system began "immediately" following FDA approval, announced Feb. 11, at a price of $295,000 each, according to the firm.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.